Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc (USA)  

(Public, NASDAQ:TTHI)   Watch this stock  
Find more results for TTHI
1.52
Aug 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.66 - 2.75
Open     -
Vol / Avg. 0.00/41,769.00
Mkt cap 57.36M
P/E     -
Div/yield     -
EPS -0.49
Shares 38.80M
Beta 1.63
Inst. own 24%
Sep 13, 2016
Q4 2016 Transition Therapeutics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.29% -86.61%
Return on average equity -58.00% -107.14%
Employees 18 -
CDP Score - -

Address

101 College St Suite 220
TORONTO, ON M5G 1L7
Canada
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.